Agenus Inc
AGEN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$6.16
KIRA · Stoqly’s AI analyst, in plain words
- Agenus Inc had $114M of revenue in fiscal 2025, up 10.4% on the year before. Over five years, revenue changed +5.3% a year on average.
- Its operating margin was −17.7%, up 98.8 pts: of every 100 in sales, about −18 is left after running the business.
- Agenus Inc lost $3.1M in fiscal 2025.
- Free cash flow was −$77.2M in fiscal 2025, −67.6% of revenue.
- Agenus Inc owes $41.8M more than it holds in cash.
Market cap
$255M
P/E
2.0x
Revenue
$114M
Net income
−$3.1M
Free cash flow
−$77.2M
Operating margin
−17.7%
Agenus Inc in 30 seconds · fiscal 2025
Are sales growing?
+10.4%
Yes. Sales grew 10.4% last year.
Does it make a profit?
−2.7%
No. It lost money last year.
Does profit turn into cash?
−67.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
2.0x
One share costs 2.0 times its yearly profit per share.
What Agenus Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- AGENUS INC
- CIK
- 0001098972
Agenus Inc · AGEN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $296M | $98.0M | $156M | $103M | $114M |
| Revenue growth | 235.3% | −66.8% | 59.5% | −33.8% | 10.4% |
| Gross margin | 98.8% | 89.2% | 98.0% | 99.5% | 99.1% |
| Operating margin | 8.7% | −183.0% | −102.1% | −116.4% | −17.7% |
| Net income | −$28.7M | −$231M | −$257M | −$232M | −$3.1M |
| Net margin | −9.7% | −235.3% | −164.7% | −224.5% | −2.7% |
| Diluted EPS | −$0.11 | −$15.64 | −$13.75 | −$10.59 | $0.00 |
| Cash | |||||
| Cash from operations | $10.1M | −$175M | −$224M | −$158M | −$77.2M |
| Capital expenditure | $33.8M | $53.1M | $10.0M | $0.6M | $0.0M |
| Free cash flow | −$23.7M | −$228M | −$234M | −$159M | −$77.2M |
| FCF margin | −8.0% | −233.0% | −149.8% | −153.6% | −67.6% |
| Share count change | 32.7% | 6,054.2% | 27.0% | 20.0% | 38.5% |
| Debt and strength | |||||
| Cash and short-term investments | $307M | $193M | $76.1M | $40.4M | $3.0M |
| Debt incl. finance leases | $14.2M | $33.4M | $28.1M | $38.0M | $44.8M |
| Shareholders' equity | $34.4M | −$61.3M | −$160M | −$326M | −$271M |
| Net debt / EBITDA | −9.0x | — | — | — | — |
| Current ratio | 2.1x | 1.1x | 0.4x | 0.2x | 0.4x |
| Interest coverage | — | −2.8x | −1.5x | −1.0x | −0.4x |
| Returns and quality | |||||
| Return on tangible equity | −2,243.2% | — | — | — | — |
| Piotroski F-score | 7 | 1 | 3 | 2 | 3 |
| Altman Z'' | −7.5 | −16.1 | −27.1 | −40.7 | −38.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Agenus Inc · AGEN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.16 a share, the company is worth $255M: 2.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001098972). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.